Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group
Open Access
- 1 April 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (4) , 665-667
- https://doi.org/10.1128/aac.34.4.665
Abstract
We conducted a randomized controlled trial of orally administered amifloxacin versus trimethoprimsulfamethoxazole (TMP-SMX) as treatments of acute uncomplicated urinary tract infection in women. Amifloxacin at a dosage of 200 mg twice a day appeared as safe and effective as TMP-SMX, but amifloxacin at 400 mg twice a day tended to cause adverse events more frequently than did TMP-SMX.This publication has 8 references indexed in Scilit:
- Confidence Intervals for Reporting Results of Clinical TrialsAnnals of Internal Medicine, 1986
- Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolatesJournal of Antimicrobial Chemotherapy, 1986
- Antibacterial Activity of Amifloxacin (WIN 49, 375), a New Quinolone AgentDiagnostic Microbiology and Infectious Disease, 1985
- THE COMPARATIVE ACTIVITY OF 12 4-QUINOLONE ANTIMICROBIALS AND SULFADIAZINE AGAINST NEISSERIA-MENINGITIDIS1985
- In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patientsAntimicrobial Agents and Chemotherapy, 1984
- In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillinAntimicrobial Agents and Chemotherapy, 1984
- Antibiotic susceptibility testing by a standardized single disk method.1966
- ANTIBIOTIC SUSCEPTIBILITY TESTING BY A STANDARDIZED SINGLE DISK METHOD1966